Montis Biosciences
Leuven, BE · Founded 2020 · 15 employees on LinkedIn · 5 known investors
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma. The biotech company is based near Leuven, Belgium.
Founders & leadership
FG
Federico GrossiClinical Advisor & Acting CMO
Investors · 5
Founder mafia
2 people who came through Montis Biosciences went on to found or lead other companies.
Frequently asked questions
- What does Montis Biosciences do?
- Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma. The biotech company is based near Leuven, Belgium.
- Who are Montis Biosciences's investors?
- Montis Biosciences's investors include Droia Ventures, ALSA Ventures, Pfizer Ventures, VIB, Pfizer Venture Investments.
- Where is Montis Biosciences headquartered?
- Montis Biosciences is headquartered in Leuven, BE.